- 8017 Labana Ct, Canton Township, MI 48187
- +1 (734) 418 2537
- info@a2zbillings.com
A single cancer patient can generate radiation claims, laboratory claims, infusion claims, and research claims within the same month, each governed by its own rule set. A gap in any one of them is easy to miss and expensive to leave unresolved.
Medical oncology, radiation oncology, surgery, and pathology often treat the same patient in the same month. Coordinating who bills what, and when, keeps evaluation and management services from overlapping or getting denied as duplicates.
Radiation delivered in a hospital outpatient department is paid under a different system than the same treatment delivered in a freestanding center, with the professional and technical components split apart in one setting and combined in the other.
A patient in a clinical trial needs routine standard-of-care items separated from the investigational items the trial sponsor covers. Billing the wrong one to Medicare or a commercial payer creates a compliance problem, not just a denial.
Chemotherapy administration is only one part of a cancer program's billing picture. These are the areas that create the most rework when they aren't planned for in advance.
Radiation oncology bills the planning process separately from delivery, and the level reported has to match the number of treatment areas, the blocking, and the imaging actually used to build the plan.
Physician management of a radiation course is billed in units tied to a defined number of fractions, not simply once a week, and the visit has to be documented against the treatment review it represents.
Freestanding centers often bill radiation services globally, while hospital-based programs have to separate the physician's professional work from the facility's technical service. A missed split leaves one side of the claim unpaid.
Institutional claims for many molecular diagnostic tests require a unique test identifier tied to the specific assay, not just the CPT code. A claim filed without it can be extended indefinitely.
A patient enrolled in a qualifying clinical trial needs the investigational item billed separately from routine standard-of-care items, and the trial number, diagnosis code, and modifier all have to agree with each other.
When a separately identifiable visit happens on a treatment day, modifier 25 keeps the evaluation and management service from bundling into the administration and dropping its payment.
These patterns surface on radiation, laboratory, and research claims for cancer programs. Each is preventable with the right documentation pulled at the right time.
Radiation treatment planning is graded by complexity, from a single treatment area with simple blocking to multiple areas with custom shielding and special techniques. The physician's documentation has to describe the treatment areas, the ports, and the technique used, because the level billed follows directly from what's written in the plan, not from the modality alone.
Weekly treatment management is tied to a defined count of fractions, and the note supporting it should reflect an actual review of the patient's course, not a restatement of the plan from the first visit. A record that looks identical week to week invites a payer to ask whether the review happened at all.
Molecular and genomic tests are covered under local policies that name the specific assay, the clinical indication, and the ordering requirements. The ordering physician's documentation needs to connect the diagnosis to the reason the test was ordered, and the laboratory needs its assigned test identifier on file before the claim goes out, not after a denial arrives.
Clinical trial documentation has to separate what the protocol requires from what standard care would have required anyway. A coverage analysis, built before the first patient enrolls, maps every protocol service to a billing category so the claim reflects that determination instead of a guess made at the time of service.
Not every service in a cancer program runs through the medical benefit. An oral oncolytic can route to a specialty pharmacy under the prescription benefit, a genomic panel can require its own separate authorization apart from the drug that depends on its result, and treating one as though it clears the other creates a gap the practice has to absorb.
Genomic and molecular tests are frequently reviewed against a local coverage policy tied to a specific diagnosis and a specific assay, not to molecular testing in general. A companion diagnostic ordered to determine eligibility for a targeted therapy has to satisfy its own coverage criteria before the drug's authorization means anything.
Clinical trial enrollment doesn't remove the need for verification. Standard-of-care items in the protocol still need eligibility and benefit confirmation like any other service, and the sponsor's coverage of investigational items has to be documented separately so the two are never billed to the same payer by mistake.
A cancer program's revenue cycle doesn't end with one claim type. It runs across planning, testing, treatment, and research at the same time, and each stream is tracked from verification through reconciliation.
Each service is routed to the correct benefit, medical, pharmacy, or research, before anything is scheduled.
Treatment planning and testing are documented to the level the record actually supports.
Professional and technical components are separated where the site of service requires it.
Claims carry the identifiers each payer needs, from test codes to trial numbers.
Remittances are checked against the fraction count, the test result, and the trial's billing grid.
We support radiation oncology practices, molecular labs, and hospital-affiliated cancer programs across the United States, with a process built around the parts of oncology billing that fall outside a standard infusion claim.
Planning and simulation codes are reviewed against the documented treatment areas and technique before a claim goes out, so the level billed matches what the record supports.
When radiation, medical oncology, and surgery treat the same patient, visit and procedure codes are checked against each other so services don't overlap or duplicate.
Drugs, tests, and trial services are routed to the correct benefit before scheduling, so a claim isn't built on the wrong assumption from the start.
Clinical trial claims are checked against the coverage analysis for that protocol, so routine and investigational costs land with the right payer the first time.
A course of radiation involves distinct stages, planning, simulation, dosimetry, and delivery, and each has its own code because each represents separate physician and technical work. A hospital-based program also has to split many of these into professional and technical components, which adds more lines but reflects two separate services rather than duplicate billing.
It's a unique identifier assigned to a specific molecular or genomic test through Medicare's molecular diagnostics program. Institutional claims for many of these tests are processed alongside that identifier, and a test performed without one registered can be treated as an unlisted service that pends until it's resolved.
Routine items, the ones a patient would have received as standard care regardless of the trial, are billed with modifier Q1, while the investigational item or service being studied is billed with modifier Q0. A coverage analysis completed before enrollment determines which category each protocol service falls into.
A freestanding center is typically paid under one fee schedule that combines the physician and technical work into a single payment. A hospital outpatient department is paid under a separate system that splits those two components apart, which changes both the amount and the number of claim lines for the identical treatment.
Evaluation and management services and procedure codes across all three specialties are reviewed together for the same patient and the same period, so a visit tied to one treatment plan isn't also billed as though it supported a separate one.
Not exactly. A genomic or molecular test is usually reviewed against a coverage policy tied to the specific assay and the diagnosis it's ordered for, separate from any authorization tied to a drug the result might support. Clearing one doesn't automatically clear the other.
If radiation claims, molecular test billing, or research claims are getting held up, denied, or paid inconsistently, we'll review your current workflow and show you where the gaps are.
